What is William Blair’s Forecast for Medpace Q3 Earnings?

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities research analysts at William Blair decreased their Q3 2025 earnings estimates for Medpace in a research report issued on Tuesday, February 11th. William Blair analyst M. Smock now anticipates that the company will post earnings of $2.99 per share for the quarter, down from their prior forecast of $3.18. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace’s Q4 2025 earnings at $2.93 EPS, FY2025 earnings at $12.12 EPS, Q1 2026 earnings at $3.38 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.50 EPS and Q4 2026 earnings at $3.57 EPS.

MEDP has been the topic of several other research reports. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Price Performance

MEDP stock opened at $340.17 on Thursday. The firm has a market capitalization of $10.36 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.85 and a beta of 1.36. The company’s 50 day simple moving average is $343.70 and its 200-day simple moving average is $348.83. Medpace has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%.

Institutional Trading of Medpace

Several large investors have recently modified their holdings of MEDP. R Squared Ltd bought a new stake in shares of Medpace during the 4th quarter worth $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace during the 4th quarter worth $31,000. Stone House Investment Management LLC bought a new stake in shares of Medpace during the 3rd quarter worth $33,000. Ashton Thomas Securities LLC bought a new stake in shares of Medpace during the 3rd quarter worth $37,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after buying an additional 110 shares during the period. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.